Outcomes associated with switching from monotherapy to adjunctive therapy for patients with partial onset seizures

References

• World Health Organization. Epilepsy: fact sheet N999 October 2012. Available from: www.who.int/mediacentre/factsheets/fs999/en/ [Last accessed on 24 October 2014]
   Google Scholar
• Centers for Disease Control and Prevention. Targeting epilepsy: improving the lives of people with one of the nation’s most common neurological conditions. Chronic disease at a glance reports 2011. Available from: www.cdc.gov/chronicdisease/resources/publications/aag/epilepsy.htm [Last accessed on 24 October 2014]
   Google Scholar
• Banerjee PN, Filippi D, Allen Hauser W. The descriptive epidemiology of epilepsy-a review. Epilepsy Res 2009;85:31-45
   PubMed Web of Science ®Google Scholar
• Baulac M, Leppik E. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res 2007;75(2-3):75-83
   PubMedGoogle Scholar
• Ben-Menachem E. Medical management of refractory epilepsy- practical treatment with novel antiepileptic drugs. Epilepsia 2014;55(Suppl 1):3-8
   PubMed Web of Science ®Google Scholar
• Simoens S. Pharmacoeconomics of anti-epileptic drugs as adjunctive therapy for refractory epilepsy. Expert Rev Pharmacoecon Outcomes Res 2010;10:309-15
   PubMed Web of Science ®Google Scholar
• Faught E. Should monotherapy for epilepsy be reconsidered? US Neurology 2009;5:59-62
   Google Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Eng J Med 2000;342:314-19
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000;9:464-8
   PubMed Web of Science ®Google Scholar
• Chung SS. Lacosamide: new adjunctive treatment option for partial-onset seizures. Expert Opin Pharmacother 2010;11:1595-602
   PubMed Web of Science ®Google Scholar
• Kwan P, Arzimangolou A, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia 2010;51:1069-77
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Birnbaum HG, Kidolezi Y, et al. Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States. Epilepsia 2010;51:838-44
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Birnbaum HG, Kidolezi Y, et al. Economic burden of epilepsy among the privately insured in the US. Pharmacoeconomics 2010;28:675-85
   PubMed Web of Science ®Google Scholar
• Lee WC, Hoffmann MS, Arcona S, et al. A cost comparison of alternative regimens for treatment-refractory partial seizure disorder: an econometric analysis. Clin Ther 2005;27:1629-38
   PubMedGoogle Scholar
• Lee WC, Arcona S, Thomas SK, et al. Effect of comorbidities on medical care use and cost among refractory patients with partial seizure disorder. Epilepsy Behav 2005;7:123-6
   PubMedGoogle Scholar
• Chen S, Wu N, Boulanger L, Sacco P. Antiepileptic drug treatment patterns and economic burden of commercially-insured patients with refractory epilepsy with partial onset seizures in the United States. J Med Economics 2013;16:1-9
   PubMedGoogle Scholar
• Yoon D, Frick KD, Carr DA, et al. Economic impact of epilepsy in the United States. Epilepsia 2009;50:2186-91
   PubMed Web of Science ®Google Scholar
• Cramer JA, Wang ZJ, Chang E, et al. Healthcare utilization and costs in children with stable and uncontrolled epilepsy. Epilepsy Behav 2014;32:135-41
   PubMed Web of Science ®Google Scholar
• Margolis JM, Chu B, Wang ZJ, et al. Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action. JAMA Neurol 2014;71:985-93
   PubMed Web of Science ®Google Scholar
• Shorvon SD, Reynolds EH. Reduction in polypharmacy for epilepsy. Br Med J 1979;2:1023-5
   PubMedGoogle Scholar
• Schmidt D. Reduction of two-drug therapy in intractable epilepsy. Epilepsia 1983;24:368-76
   PubMed Web of Science ®Google Scholar
• Schmidt D. Two antiepileptic drugs for intractable epilepsy with complex-partial seizures. J Neurol Neurosurg Psychiatry 1982;45:1119-24
   PubMed Web of Science ®Google Scholar
• French JA, Faught E. Rational polytherapy. Epilepsia 2009;50(Suppl 8):63-8
   PubMed Web of Science ®Google Scholar
• St Louis E. Truly “rational” polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects. Current Neuropharmacol 2009;7:96-105
   PubMed Web of Science ®Google Scholar
• Deckers CLP, Yechiel AH, Keyser A, et al. Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study. Epilepsia 2001;42:1387-94
   PubMed Web of Science ®Google Scholar
• Beghi E, Gatti G, Tonini C, et al. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res 2003;57:1-13
   PubMed Web of Science ®Google Scholar
• Begley CE, Famulari M, Annegers JF, et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000;41:342-51
   PubMed Web of Science ®Google Scholar
• Lasoń W, Dudra-Jastrzębska M, Rejdak K, Czuczwar SJ. Basic mechanisms of antiepileptic drugs and their pharmacokinetic/pharmacodynamic interactions: an update. Pharmacol Rep 2011;63(2):271-92
   PubMed Web of Science ®Google Scholar
• The human epilepsy project. Available from: http://humanepilepsyproject.org/ [Last accessed 15 September 2014]
   Google Scholar
• Schiller Y, Naijar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology 2008;70:54-65
   PubMed Web of Science ®Google Scholar
• Shorvon SD, Goodridge DM. Longitudinal cohort studies of the prognosis of epilepsy: contribution of the National General Practice Study of Epilepsy and other studies. Brain 2013;11136:3497-510
   Google Scholar